Shreyas V Desai, Bhavna Joshi, Umesh Upadhyay
Shreyas V Desai1, Prof. Bhavna Joshi2, Dr. Umesh Upadhyay3
1Student, Department of Pharmacy, Sigma Institute of Pharmacy, Bakrol, Ajwa, Vadodara.
2Associate Professor, Department of Pharmacy, Sigma Institute of Pharmacy, Bakrol, Ajwa, Vadodara.
3Principal, Department of Pharmacy, Sigma Institute of Pharmacy, Bakrol, Ajwa, Vadodara.
Volume - 12,
Issue - 4,
Year - 2020
Niosomes are non-ionic surfactant based multilamellar on unilamellar vesicles in which a fluid arrangement of solute is completely encased by a membrane because of the association of surfactant macromolecules as bilayer. The drug targeting is a kind of phenomenon in which drug gets distributed in the body in such a manner that the drug interacts with the target tissue at a cellular or sub cellular level to achieve a desired therapeutic response at desire site without undesirable interactions at other sites. Niosomes can be achieved by modern methods of targeting the drug delivery system such as niosomes. Which are the biodegradable, non-toxic, more stable and inexpensive, another way to deal with liposomes. It can be used as carriers of amphiphilic and lipophilic drug. They are also handling and storage of niosomes requires no special conditions. The fundamental object of this review is the use of niosome innovation is utilized to treat various diseases, noisome have great open door in research and useful for research in pharma company. Niosomes have great drug delivery potential for targeted delivery of anti-infective and anti-cancer agents.
Cite this article:
Shreyas V Desai, Bhavna Joshi, Umesh Upadhyay. An Overview on Niosomes As Novel Drug Delivery Systems. Res. J. Pharma. Dosage Forms and Tech.2020; 12(4):271-281. doi: 10.5958/0975-4377.2020.00045.2
Shreyas V Desai, Bhavna Joshi, Umesh Upadhyay. An Overview on Niosomes As Novel Drug Delivery Systems. Res. J. Pharma. Dosage Forms and Tech.2020; 12(4):271-281. doi: 10.5958/0975-4377.2020.00045.2 Available on: https://rjpdft.com/AbstractView.aspx?PID=2020-12-4-7
1. Sanklecha VM, Pande VV, Pawar SS, Pagar OB and Jadhav AC. Review on Niosomes. Austin Pharmacol Pharm. 2018; 3(2): 1 – 7.
2. Kartik et al. Niosomes: an Unique DrugDelivery System.Pharma Science Monitor. Jul-Sep 2016,7(3): 85 – 99.
3. Deepak et al. Niosomes–A NovelVascularApproach. World Journal of Pharmacy and Pharmaceutical Sciences. 2016,5(12): 1586–1592.
4. A. Krishna Sailaja. Niosomes–A Novel Drug Carries for Drug Targeting. Mintage Journal Of Pahrmaceutical and Medical Sciences.Jan-March 2016, 5(1): 8 – 15.
5. Kaur et al. Niosomes – PresentScenario And Future Aspects. Journal of Drug Delivery and Therapeutics. 2018, 8(5):35-43.
6. Ahmad and Kumar.Niosomes–A Promising Carrier for Drug Delivery.Int. J. Res. Dev. Pharm. L. Sci.July - August 2018; 7(4): 3015-3021.
7. Sharma D, Ali AAE, Aate JR. Niosomes as Novel Drug Delivery System. PharmaTutor. 2018; 6(3): 58-65.
8. N.B. Mahale et al. Niosomes: Novel sustained release nonionic stable vesicular systems — Anoverview. Advances in Colloid and Interface Science 183–184 (2012): 46–54.
9. Anita R. Desai et al. Development and characterization of niosomal drug delivery of a-tocopherol. International Journal of Chemical and Analytical Science 2010, 1(7): 146-148.
10. Preethi Sudheerand Kar Kaushik. Review on Niosomes –A Novel Approach for Drug Targeting. Journal of Pharmaceutical Research. January - March 2015, 14(1): 20-25.
11. Mahmoud Gharbavi et al. Niosome: A Promising Nanocarrier for Natural DrugDelivery through Blood-Brain Barrier. Advances In Pharmacological Sciences. 2018: 1 – 15.
12. S. B. Shirsand, Ganesh G. Keshavshetti. Recent Advances In Niosomel Drug Delivery. Life Science Informatics Publications.May – June 2019, 5(3): 514 – 531.
13. Reddy et al. Niosomes As Nanocarrier System. IJPSR. 2012. 3(6): 1560-1568.
14. Bhattacharya, et al. Preparation and Evaluation of Diclofenac Sodium Niosomes Using Round Bottom Flask Method.Asian Journal of Pharmaceutics. Apr-Jun 2020. 4 (2): 188– 194.
15. Abd El hakim Ramadan et al. Controlled Release Niosomal Gel as a Colloidal Carrier for Topical Drug Delivery of Ketorolac TromethamineIjppr.Human, 2016; Vol. 7 (1): 528-539.
16. Citation: Syeda Saniya Fatima et al. Niosomes as Nanoparticular Drug Carriers Ijppr.Human, 2017, 9 (3): 117-133.
17. Muzzalupo and Tavano. Niosomal Drug Delivery ForTransdermal Targeting: Recent Advances. Research and Reports in Transdermal Drug Delivery 2012.V-4: 23–33.
18. Mohamed A. Raslan et al. The Use of Ketoprofen Niosomes For Formulations Of Sustain Release Tablets Dosage form. Az. J. Pharm Sci.September, 2012. V-46: 90 – 100.
19. Sharma et al. Advancement in Novel Drug Delivery System: Niosomes. Journal of Drug Delivery and Therapeutics. 2019; 9(3-s):995-1001.
20. Pravina Gurjar et al. Niosomes: A Promising Pharmaceutics Drug Delivery. Int.J. Pharm Anal. 2014, 2(5):425-431.
21. Amit Kumar Rai et al. Niosomes: An Approach to Current Drug Delivery Review. International Journal of Advances in Pharmaceutics. 2017; 06(02): 41-48.
22. Namrata Mishra et al. Formulation and In-vitro Evaluation of Niosomes of Aceclofenac. Journal of Scientific and Innovative Research 2014; 3(3): 337-341.
23. Srikanth et al., Formulations and Evaluations of NystatinLoaded Niosomes, IJPSR, 2013;4(5): 2015-2020.
24. Kumar et al. Formulations and Evaluation Niosomal Suspension of Cefixime.Asian J Pharm Clin Res,2017, 10(5): 194-201.
25. Vilegave Kailash et al., Niosomes (Non-Ionic surfactant vesicles) preparation and stability inbiological environment. International Journal of Research in Controlled Release 2013, 1(1):1-9.
26. Satish Rane et al., Niosomes: A Non-Ionic Surfactant Based Vesicles as a Carriers for DrugDelivery. Int. J. Pharm. Sci. Rev. Res., July - August 2018; Article No. 29, 51(1): 198-213.
27. Arora Rajnish et al., Release Studies of Ketoprofen Niosome Formulation. J. Chem. Pharm. Res., 2010, 2(1): 79-82.
28. Arul jothy M etal., An Overview On Niosome As Carrier In Dermal Drug Delivery J. Pharm. Sci. and Res., 2015, 7(11): 923-927.
29. Mahmoud K, Mohamed M, Amr I, Dina L. An Overview on Niosomes: ADrug Nanocarrier.Drug Des Int Prop Int J, 2018, 1(5): 143-151.
30. Samyuktha Rani et al., Niosomal Formulation of Orlistat: Formulation and In-Vitro Evaluation, Int. J. Drug Dev. and Res., July-Sep 2011, 3 (3): 300-311.
31. Khalid M. El-Say et al., Development and Optimization of Diclofenac Sodium Niosomes Using Response Surfaces Methodology, Az. J. Pharm. Sci., September, 2009, 40: 272-286.
32. El-ridy et al., Niosomes as a Novel Pharmaceutical Formulation Encapsulating theHepatoprotective Drug Silymarin, Int J Pharm Pharm Sci, 2011, 4(1): 549-559.
33. EL-Mofty et al., Niosomes: Do They Increase the Potency of Topical Natamycin KetorolacFormula in Treating Aspergillus Keratitis? An Experimental Study, Journal of Ocular Pharmacology and Therapeutics, 2020: 1-10.
34. Saliha Durak et al., Niosomal Drug Delivery Systems for Ocular Disease—Recent Advances and Future Prospects, Nanomaterials 2020, 10, 1191: 1-29.
35. Rampal Rajera et al., Niosomes: A Controlled and Novel Drug Delivery System, Biol. Pharm. Bull.,2011, 34(7): 945—953.
36. Karim, et al., Niosome – A future of targeted drug delivery systems, Journal of Advanced Pharmaceutical Technology and Research, Oct-Dec 2010, 1(4): 374-380.
37. ELSIE OOMMEN et al., Niosome entrapped B-cyclodextrin methotrexate complex as a drug deliverysystem, Indian Journal of Pharmacology 1999; 31: 279-284.
38. P.U. Mohamed Firthouse et al., Formulation and Evaluation of Miconazole Niosomes, Int.J. PharmTech Res., 2011,3(2): 1019-1022.
39. Sayed H. Auda et al., Niosomes as transdermal drug delivery systemfor celecoxib: in vitro and in vivo studies, Polymer Bulletin, November2015: 1-18.
40. Nasir et al., Niosomes: an excellent tool for drug delivery, IJRPC 2012, 2(2): 478-487.
41. Dr. Prabha Singh et al., Niosomes-A Novel tool for Anti-ageing Cosmeceuticals, Indo American Journal of Pharmaceutical Research, 2016, 6(10): 6691-6703.
42. Yadav Sunil Kumar et al., Niosomes: An approach towards targeted drug delivery system, International Journal of Institutional Pharmacy and Life Sciences, November-December 2016 6(6): 39-52.
43. Biswas et al., Niosomes in ocular drug delivery, ejpmr, 2017,4(7): 813-819.
44. Mujoriya et al., Niosomes - challenge in preparation for pharmaceutical scientist, Int J App Pharm, 2011, 3(3): 11-15.
45. Bansal, et al., Cefdinir niosomes for oral delivery, Journal of Pharmacy and Bioallied Sciences October-December 2013, 5(4):318-325.
46. Pratap S. Jadon et al., Enhanced Oral Bioavailability of Griseofulvin via Niosomes, AAPS PharmSciTech, December 2009, 10(4): 1186-1192.
47. Didem Ag Seleci et al., Rapid Microfluidic Preparation of Niosomes for Targeted Drug Delivery, Int. J. Mol. Sci. 2019, 20, 4696: 1-12.
48. M. Barani, et al., A new formulation of hydrophobin-coated niosome as a drug carrier to cancercells, Materials Science and Engineering C 113 (2020) 110975: 1-8.
49. Banyi Lu et al., Niosomal Nanocarriers for Enhanced Skin Deliveryof Quercetin with Functions of Anti-Tyrosinase and Antioxidant, Molecules 2019, 24, 2322: 1-17.
50. Hamid Saeed Shah et al., Release Studies on Niosomes Containing Fatty Alcohols as Bilayer StabilizersInstead of Cholesterol, Journal of Colloid and Interface Science,2019: 1-10.
51. Parmar and Brijesh, Niosomes as Transdermal Drug Delivery System, Biomed Res J 2018;5(2):54–63.
52. Zehra Ceren Ertekin et al., Stability Studies on Piroxicam Encapsulated Niosomes, Current Drug Delivery, 2015, 12(2): 192-199.
53. Mothilal et al., Screening and optimization of valacyclovir niosomes by design ofexperiments, Int J App Pharm, 2018, 10(1): 79-85.
54. Rehman et al., Development of niosomal formulations loaded with cyclosporine A andevaluation of its compatibility, Tropical Journal of Pharmaceutical Research August 2018; 17 (8): 1457-1464.
55. Ruckmani and Sankar, Formulation and Optimization of Zidovudine Niosomes, AAPS Pharm Sci Tech, September 2010, 11(3): 1119-1127.
56. Khan et al., In Vitro In Vivo Evaluation of Niosomal Formulation of Famotidine, Int J Pharm Pharm Sci, January 2020, 12(3): 15-22.
57. Sandeep kumar sharma et al., span-60 niosomal oral suspension of fluconazole: formulationand in vitro evaluation, Journal of Pharmaceutical Research and health Care, Octomber 2009, 1(2): 142-156.
58. Salih et al., Formulation and in vitro evaluation of rosuvastatin calcium niosomes, Int J Pharm Pharm Sci, Oct 2013, 5(4): 525-535.
59. Sakthivel et al., Formulation and in vitro evaluation of niosomes containing Oxcarbazepine, Int J Pharm Pharm Sci, Jun 2012,4(3): 563-567.
60. Sharma PK et al., Anti-Diabetic Activity of Lycopene Niosomes: Experimental Observation, Journal of Pharmaceutics and Drug Development, 2017, 4(1): 1-8.
61. Sharma PK et al., Novel Encapsulation of Lycopene in Niosomes and Assessment of itsAnticancer Activity, Journal of Bioequivalence and Bioavailability, August 2016, 8(5): 224-232.
62. Mothilal et al., Niosomes as an Emerging Formulation Tool For Drug Delivery-A Review, Int J App Pharm, 2019, 11(2): 7-15.